Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results for the Quarter ended 30th September, 2026 and declaration of Second Interim Dividend, if any

29th October, 2026 Corporate Relationship Department Manager – Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400 001. Mumbai 400 051. Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Notice of Board Meeting under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, the 13th day of November 2026 to consider among other things, the following items of business and related matters: Sl. No. Item of Business 1 To consider the Unaudited Financial Results for the quarter and half year ended 30th September 2026 2 To consider the declaration of second interim dividend, if any, for the financial Year ending 2026-27 Further to our earlier intimation(s) dated 30th September, 2026 & 22nd October, 2026 regarding the closure of the Trading Window, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company’s Code of Conduct, we wish to inform you that the Trading Window for dealing in the securities of the Company was closed for all Directors, Designated Persons, their immediate relatives, and all other connected persons with effect from October 30, 2026 till 15th November, 2026 (both days inclusive). Trading window will be re-opened on 16th November, 2026. Thanking you, Yours faithfully, For NATCO Pharma Limited Chekuri Venkat Ramesh Company Secretary & Compliance Officer